Homepage Top Section2

TILT-123 has been engineered to selectively replicate only in cancer cells that produce the TNFa and IL-2 immunostimulatory cytokines locally at the tumour as shown in various in

The EC has approved Talzenna as monotherapy treatment for adult patients with germline breast cancer susceptibility gene (gBRCA)1/2-mutations, who have human epidermal growth factor receptor 2-negative (HER2-) locally

As part of the multi-year collaboration, both the firms will involve in the discovery, development and commercialisation of a pipeline of novel targeted protein degradation drugs for patients

The late-stage trial met its primary multi-component endpoint and showed that linaclotide, in comparison to placebo, improved the overall abdominal symptoms of bloating, discomfort and pain in adult

With the approval, Lynparza can be used as a maintenance treatment for adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian,

Guselkumab, which was subcutaneously injected in the participating patients, was assessed for its efficacy and safety in the DISCOVER 1 and 2 trials compared to placebo. Janssen said

The regulator has approved Keytruda as monotherapy and also in combination with a commonly used chemotherapy regimen – platinum and fluorouracil (FU). The approval is for first-line treatment

The accelerated approval for the Polivy, BR combination is for treatment of adult patients with DLBCL whose condition is either relapsed or refractory (R/R) and had been subjected

As per the terms of the deal, Theramex will have exclusive commercialisation rights for BIJUVA and IMVEXXY outside the US with the exception of Canada and Israel where